Scholar Rock Holding (SRRK) Other Accumulated Expenses (2017 - 2026)
Scholar Rock Holding's quarterly Other Accumulated Expenses came in at $775000.0 in Q1 2026, up 3.47% year-on-year from $749000.0 in Q1 2025, and down 45.35% quarter-over-quarter from $1.4 million in Q4 2025.
Scholar Rock Holding has reported Other Accumulated Expenses for 10 years, with the latest figure at $775000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Accumulated Expenses rose 3.47% year-over-year to $775000.0; the trailing twelve-month figure through Mar 2026 stood at $775000.0 (up 3.47% YoY), and the FY2025 full-year result was $1.4 million, up 61.32% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $775000.0, down from $1.4 million in the prior quarter.
- The five-year high for Other Accumulated Expenses was $1.4 million in Q4 2025, with the low at $85000.0 in Q4 2023.
- Average Other Accumulated Expenses over 5 years is $781647.1, with a median of $831000.0 recorded in 2024.
- Year-over-year, Other Accumulated Expenses tumbled 89.8% in 2023 and jumped 934.12% in 2024.
- Tracing SRRK's Other Accumulated Expenses over 5 years: stood at $833000.0 in 2022, then sank by 89.8% to $85000.0 in 2023, then jumped by 934.12% to $879000.0 in 2024, then surged by 61.32% to $1.4 million in 2025, then tumbled by 45.35% to $775000.0 in 2026.
- The last three Other Accumulated Expenses figures came in at $775000.0 (Q1 2026), $1.4 million (Q4 2025), and $867000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 775,000.00 |
| Dec 31, 2025 | 1.42 Mn |
| Sep 30, 2025 | 867,000.00 |
| Jun 30, 2025 | 1.13 Mn |
| Mar 31, 2025 | 749,000.00 |
| Dec 31, 2024 | 879,000.00 |
| Sep 30, 2024 | 831,000.00 |
| Jun 30, 2024 | 941,000.00 |
| Mar 31, 2024 | 914,000.00 |
| Dec 31, 2023 | 85,000.00 |
| Sep 30, 2023 | 825,000.00 |
| Jun 30, 2023 | 762,000.00 |
| Mar 31, 2023 | 121,000.00 |
| Dec 31, 2022 | 833,000.00 |
| Sep 30, 2022 | 731,000.00 |
| Jun 30, 2022 | 583,000.00 |
| Mar 31, 2022 | 846,000.00 |
| Dec 31, 2021 | 460,000.00 |
| Sep 30, 2021 | 228,000.00 |
| Jun 30, 2021 | 236,000.00 |
| Mar 31, 2021 | 820,000.00 |
| Dec 31, 2020 | 476,000.00 |
| Sep 30, 2020 | 553,000.00 |
| Jun 30, 2020 | 143,000.00 |
| Mar 31, 2020 | 19,000.00 |
| Dec 31, 2019 | 16,000.00 |
| Sep 30, 2019 | 15,000.00 |
| Jun 30, 2019 | 244,000.00 |
| Mar 31, 2019 | 199,000.00 |
| Dec 31, 2018 | 14,000.00 |
| Sep 30, 2018 | 64,000.00 |
| Jun 30, 2018 | 54,000.00 |
| Dec 31, 2017 | 15,000.00 |